Interstitial and Granulomatous lung disease in inflammatory bowel disease patients.
J Crohns Colitis. 2019 Oct 11;:
Authors: Eliadou E, Moleiro J, Ribaldone DG, Astegiano M, Rothfuss K, Taxonera C, Ghalim F, Carbonnel F, Verstockt B, Festa S, Maia L, Berrozpe A, Zagorowicz E, Savarino E, Ellul P, Vavricka SR, Calvo M, Koutroubakis I, Hoentjen F, Luis FS, Callela F, Cañete Pizarro F, Soufleris K, Sonnenberg E, Cavicchi M, Wypych J, Hommel C, Ghiani A, Fiorino G, ECCO CONFER COMMITTEE
BACKGROUND: Interstitial lung (ILD) disease and Granulomatous lung disease (GLD) are rare respiratory disorders that have been associated with inflammatory bowel disease (IBD). Clinical presentation is polymorphic and aetiology is unclear.
METHODS: This was an ECCO-CONFER project. Cases of concomitant ILD or GLD and IBD or drug induced ILD/GLD were collected. The criteria for diagnosing ILD and GLD were based on definitions from the American Thoracic Society and European Respiratory Society and on the discretion of reporting clinician.
RESULTS: We identified 31 patients with ILD, majority had ulcerative colitis (UC) (n=22). Drug related ILD was found in 64% of patients. Twenty five patients (80.6%) required hospitalization and 1 required non-invasive ventilation. Causative drug was stopped in all drug related ILD and 87% of patients received systemic steroids. At follow up 16% of patients had no respiratory symptoms, 16% had partial improvement, 55% had ongoing symptoms, no data in 13%. One patient was referred for lung transplantation and 1 death from lung fibrosis was reported. We also identified 22 GLD patients, most had Crohn’s disease (CD) (n=17). Drug related GLD was found in 36% of patients. Ten patients (45.4%) required hospitalization. Causative drug was stopped in all drug related GLD and 81% of patients received systemic steroids. Remission of both conditions was achieved in almost all patients.
CONCLUSIONS: ILD and GLD although rare can cause significant morbidity. In our series over half of cases were drug related and therefore focused pharmacovigilance is needed to identify and manage these cases.
PMID: 31602473 [PubMed – as supplied by publisher]